MwanzoPRENW • NASDAQ
Prenetics
$ 0.0099
6 Mei, 20:15:00 GMT -4 · USD · NASDAQ · Kanusho
Hisa zinazouzwa Marekani
Bei iliyotangulia
$ 0.0094
Bei za siku
$ 0.0084 - $ 0.010
Bei za mwaka
$ 0.0050 - $ 0.021
Thamani ya kampuni katika soko
68.20M USD
Wastani wa hisa zilizouzwa
elfu 10.32
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD)Des 2024Mabadiliko Tangu Mwaka Uliopita
Mapato
10.49M98.76%
Matumizi ya uendeshaji wa biashara
20.47M40.98%
Mapato halisi
-16.34M3.57%
Kiwango cha faida halisi
-155.8151.49%
Mapato kwa kila hisa
——
EBITDA
-15.09M-39.39%
Asilimia ya kodi ya mapato
29.73%—
Jumla ya mali
Jumla ya dhima
(USD)Des 2024Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
70.79M22.84%
Jumla ya mali
213.58M-15.97%
Jumla ya dhima
42.23M-4.05%
Jumla ya hisa
171.35M—
hisa zilizosalia
12.98M—
Uwiano wa bei na thamani
0.00—
Faida inayotokana na mali
-18.44%—
Faida inayotokana mtaji
-22.78%—
Mabadiliko halisi ya pesa taslimu
(USD)Des 2024Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
-16.34M3.57%
Pesa kutokana na shughuli
——
Pesa kutokana na uwekezaji
——
Pesa kutokana na ufadhili
——
Mabadiliko halisi ya pesa taslimu
——
Mtiririko huru wa pesa
——
Kuhusu
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Ilianzishwa
2014
Wafanyakazi
322
Gundua zaidi
Huenda unavutiwa na
Orodha hii imetokana na maudhui uliyotafuta hivi majuzi, hisa unazofuatilia na shughuli zingine. Pata maelezo zaidi

Data na maelezo yote hutolewa “kama yalivyo” kwa madhumuni ya taarifa binafsi tu, wala hayanuii kuwa ushauri wa kifedha na hayana madhumuni ya kufanya biashara au uwekezaji, kodi, kisheria, uhasibu au ushauri mwingine. Google si mshauri wa uwekezaji wala mshauri wa kifedha na haitoi maoni au mapendekezo yanayohusiana na kampuni zozote zilizojumuishwa kwenye orodha hii au hisa zozote zilizotolewa na kampuni hizo. Tafadhali wasiliana na dalali wako au mwakilishi wa kifedha ili uthibitishe bei kabla ya kufanya biashara yoyote. Pata maelezo zaidi
Watu pia hutafuta
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu